Pre-Exposure ProphylaxisNCT05991869
Leveraging Electronic Health Record Data in a Risk Prediction Model to Increase HIV PrEP Intake in Primary Care
A study testing Point-of-care decision support intervention in people with Pre-Exposure Prophylaxis, run by Kaiser Permanente at 1 site in United States.
Trial summary
Kaiser Permanente Northern California (KPNC) has been a national leader in implementation of HIV preexposure prophylaxis (PrEP), a daily antiretroviral pill that is more than 99% effective in preventing HIV acquisition. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Pre-Exposure Prophylaxis
- What is being tested?
- Point-of-care decision support intervention
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 121 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Jun 2021to 31 Oct 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Primary care provider at Kaiser Permanente San Francisco Medical Center
- Provide primary care to adult patients
- more than 150 people without HIV on their primary care physician panel.
Who cannot join
- -
Trial locations and contacts
1 site in 1 country.
United States1 site
Kaiser Permanente Northern California Division of Research
Oakland, California, 94612
About this study
Official title: Randomized Trial Leveraging Electronic Health Record Data in a Risk Prediction Model to Increase HIV PrEP Uptake in Primary Care.
Kaiser Permanente Northern California (KPNC) has been a national leader in implementation of HIV preexposure prophylaxis (PrEP), a daily antiretroviral pill that is more than 99% effective in preventing HIV acquisition. However, many patients at risk for HIV at KPNC are not yet using PrEP, resulting in preventable infections each year. In prior work, the study team developed and validated a prediction model that used electronic health record (EHR) data from 3.7 million KPNC members to identify patients at high risk of HIV acquisition but not using PrEP. The model substantially outperformed models based only on CDC criteria for PrEP use, particularly for Black patients, a population with high HIV incidence and lower PrEP uptake. The objective of this proposal is to evaluate the feasibility of implementing this EHR-based model at the point of care to increase PrEP referrals and uptake at KPNC. The specific aims of this project are to 1) conduct provider focus groups to identify barriers and facilitators to PrEP referrals and to optimize the delivery mechanism of our clinical decision support intervention, 2) evaluate the feasibility and acceptability of a clinical decision support intervention for primary care providers (PCPs) to increase PrEP referrals and uptake among high-risk patients, and 3) assess patient- and provider-based characteristics associated with PrEP referrals and uptake. To accomplish these aims, the study team proposes a randomized controlled trial of a clinical decision support intervention for PrEP, which involves alerting KP San Francisco (KPSF) Adult and Family Medicine PCPs about patients identified by our prediction model as being at high risk for HIV acquisition prior to in-person clinic visits. We will compare PrEP referrals and uptake among patients who are seen by PCPs randomized to intervention and usual care study arms using an intention-to-treat analysis.
Read the detailed description
Study Design This is a randomized controlled trial among PCPs at KPSF to evaluate the feasibility of implementing a decision support intervention for PrEP and its impact on PrEP referrals and uptake among patients predicted to be at high risk for incident HIV infections. Aim 1 will consist of focus groups with PCPs to identify barriers and facilitators to PrEP referrals and to optimize the intervention. After first testing the proposed study intervention with two PCPs in each study arm, Aim 2 will compare PrEP referrals and uptake between members who are seen by PCPs randomized to intervention and usual care study arms. Aim 3 will evaluate provider- and patient-based factors associated with PrEP referrals and uptake among patients in the intervention arm. The trial will randomly allocate PCPs at KP San Francisco to one of two arms: 1) intervention arm that includes clinical decision support for PrEP referrals prior to visits scheduled with patients flagged as high-risk by the prediction model, or 2) usual care, with an estimated 50 PCPs in each arm. Eligible PCPs will be contacted by the study team prior to enrollment and given an opportunity to opt out of participating in this study. PCPs randomized to the usual care arm will not receive the clinical decision support intervention. The intervention will be conducted over 8 months.
Setting. KPNC is a large healthcare delivery system that provides integrated pharmacy, laboratory, and medical care to more than a third of insured individuals in California. KPSF has been chosen as the study site given the disproportionate burden of HIV in this KPNC service area. At KPSF, there are 121 Adult and Family Medicine (AFM) PCPs serving approximately 189,000 patients.
Subjects. The study team will recruit 10-15 PCPs each from the two KPSF clinical sites in San Francisco prior to randomization. Providers will be recruited at routine staff meetings and through email invitations for a one-time, 60- minute, audio-recorded focus group. The study team will assess what information PCPs would like to have included in the clinical decision support tool. Recognizing that time constraints are a barrier to all healthcare interventions, we will seek feedback from PCPs regarding their preferences for intervention delivery and timing, as well as their perceptions of facilitators and barriers to acting on the intervention. Open-ended questions will minimize bias and allow for unanticipated themes to emerge.
Randomization. PCPs who meet study criteria and do not opt-out will be randomized to one of the two study arms in a 1:1 ratio. There are 12 providers who care for both HIV-infected and uninfected patients, and allocation of this subset of providers will be balanced between the trial arms. To ensure this, the study team will use simple randomization to assign the 13 PCPs who care for both HIV-infected and uninfected patients to intervention or usual care and then use simple randomization again to assign the remaining 109 PCPs.
Specificity of the prediction model. The prediction model acts as a screening test to be followed by a provider's clinical evaluation. The study team expects that some patients with scores indicating an elevated risk for HIV acquisition will not have clinical indications for PrEP. The relationship between PCPs and patients is critical given the sensitive nature of sexual health discussions. In addition, prior to initiation of treatment with PrEP, patients will attend visits where a member of the dedicated KPSF PrEP team (NP or MD) will assess HIV risk and discuss PrEP indications, follow-up, side effects, and contraindications.
Scalability of the intervention outside KPNC. Even if the intervention is successful within KPNC, other health settings outside KPNC will need to adopt technology solutions to update risk scores, automate lists of patients with elevated risk scores, identify eligible appointments, and successfully deliver interventions to providers. While the study team's robust model that included 44 EHR variables provided the greatest predictive value for incident HIV, simpler models that included only a handful of key variables also improved identification of patients who may benefit from PrEP. The study results will provide a roadmap for successful implementation at other institutions, even if technology and EHR resources are more limited.
- Conditions
- Pre-Exposure Prophylaxis
- Being tested
- Point-of-care decision support intervention
- Keywords
- HIV, Pre-Exposure Prophylaxis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Point-of-care decision support interventionBehavioural
PCPs notified by EHR messages if they had an upcoming in-person or video visit with an eligible patient who had a predicted risk of incident HIV diagnosis of 0.2% or higher. Study team members manually sent messages marked as "high priority" one business day prior to scheduled visits, alerting PCPs that a patient may be at increased risk for acquiring HIV and may benefit from a conversation about PrEP. Additional information was provided about the study, the prediction model, clinical indications for PrEP, strategies for initiating discussions about HIV prevention and PrEP, and how to refer patients to KPSF's PrEP program. Messages did not include the numeric predicted HIV risk from the model. PCPs received a maximum of two messages per day; with the two patients with the highest predicted risk were selected. Patient with multiple visits were flagged no more than once monthly.
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | Not described Receives: Behavioral: Point-of-care decision support intervention |
| Usual Care | No intervention | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cumulative risk (%) of linkage to PrEP
linkage to PrEP care within 90 days of the first encounter, defined as first of following: PrEP discussion (ICD-10 Z29.8), referral (measured by PrEP referrals and appointments booked through e-consult, a provider-to-provider community platform embedded in the EHR ), or prescription fill for emtricitabine coformulated with tenofovir disoproxil fumarate or with tenofovir alafenamide
Measured: Within 90 days after PrEP referral.
Secondary outcomes (3)
Cumulative risk (%) of PrEP Prescription fill only
PrEP prescription fill within 90 days of the first encounter defined as pharmacy fills for emtricitabine coformulated with tenofovir disoproxil fumarate or with tenofovir alafenamide
Measured: Within 90 days after first encounter
Cumulative risk (%) of HIV Testing
Physician orders for HIV testing
Measured: within 90 days of first encounter
Cumulative risk (%) of STI Testing
Physician orders for any testing for bacterial STIs, including chlamydia, gonorrhea, or syphilis
Measured: within 90 days of first encounter
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Aug 2023
- Study start1 Jun 2021
- Primary completion30 Nov 2021
- Study completion31 Oct 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Pre-Exposure ProphylaxisStudies of the same condition, open and under way.
- More trials run by Kaiser PermanenteThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 121 participants (actual)
Sponsor and investigators
- Lead sponsor
- Kaiser Permanente
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05991869
- Sponsor's protocol ID
- DelSciPrEP 2021
- Status last verified
- Aug 2023
- First submitted
- 4 Aug 2023
- Last updated
- 15 Aug 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: There is no plan to make individual participant data available to other researchers.
Publications
Volk JE, Leyden WA, Lea AN, Lee C, Donnelly MC, Krakower DS, Lee K, Liu VX, Marcus JL, Silverberg MJ. Using Electronic Health Records to Improve HIV Preexposure Prophylaxis Care: A Randomized Trial. J Acquir Immune Defic Syndr. 2024 Apr 1;95(4):362-369. doi: 10.1097/QAI.0000000000003376.
PubMed 38412047
Study at a glance
From the registry record, last updated by the sponsor on 15 Aug 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized Trial Leveraging Electronic Health Record Data in a Risk Prediction Model to Increase HIV PrEP Uptake in Primary Care.
- ClinicalTrials.gov ID
- NCT05991869
- Acronym / sponsor ID
- DelSciPrEP 2021
- Conditions
- Pre-Exposure Prophylaxis
- Keywords
- HIV, Pre-Exposure Prophylaxis
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 121 participants (actual)
- Lead sponsor
- Kaiser PermanenteUniversity, hospital or other
- Study start
- 1 Jun 2021 (actual)
- Primary completion
- 30 Nov 2021 (actual)
- Study completion
- 31 Oct 2022 (actual)
- First posted
- 15 Aug 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Kaiser Permanente Northern California (KPNC) has been a national leader in implementation of HIV preexposure prophylaxis (PrEP), a daily antiretroviral pill that is more than 99% effective in preventing HIV acquisition. However, many patients at risk for HIV at KPNC are not yet using PrEP, resulting in preventable infections each year. In prior work, the study team developed and validated a prediction model that used electronic health record (EHR) data from 3.7 million KPNC members to identify patients at high risk of HIV acquisition but not using PrEP. The model substantially outperformed models based only on CDC criteria for PrEP use, particularly for Black patients, a population with high HIV incidence and lower PrEP uptake. The objective of this proposal is to evaluate the feasibility of implementing this EHR-based model at the point of care to increase PrEP referrals and uptake at KPNC. The specific aims of this project are to 1) conduct provider focus groups to identify barriers and facilitators to PrEP referrals and to optimize the delivery mechanism of our clinical decision support intervention, 2) evaluate the feasibility and acceptability of a clinical decision support intervention for primary care providers (PCPs) to increase PrEP referrals and uptake among high-risk patients, and 3) assess patient- and provider-based characteristics associated with PrEP referrals and uptake. To accomplish these aims, the study team proposes a randomized controlled trial of a clinical decision support intervention for PrEP, which involves alerting KP San Francisco (KPSF) Adult and Family Medicine PCPs about patients identified by our prediction model as being at high risk for HIV acquisition prior to in-person clinic visits. We will compare PrEP referrals and uptake among patients who are seen by PCPs randomized to intervention and usual care study arms using an intention-to-treat analysis.
Detailed description
Study Design This is a randomized controlled trial among PCPs at KPSF to evaluate the feasibility of implementing a decision support intervention for PrEP and its impact on PrEP referrals and uptake among patients predicted to be at high risk for incident HIV infections. Aim 1 will consist of focus groups with PCPs to identify barriers and facilitators to PrEP referrals and to optimize the intervention. After first testing the proposed study intervention with two PCPs in each study arm, Aim 2 will compare PrEP referrals and uptake between members who are seen by PCPs randomized to intervention and usual care study arms. Aim 3 will evaluate provider- and patient-based factors associated with PrEP referrals and uptake among patients in the intervention arm. The trial will randomly allocate PCPs at KP San Francisco to one of two arms: 1) intervention arm that includes clinical decision support for PrEP referrals prior to visits scheduled with patients flagged as high-risk by the prediction model, or 2) usual care, with an estimated 50 PCPs in each arm. Eligible PCPs will be contacted by the study team prior to enrollment and given an opportunity to opt out of participating in this study. PCPs randomized to the usual care arm will not receive the clinical decision support intervention. The intervention will be conducted over 8 months.
Setting. KPNC is a large healthcare delivery system that provides integrated pharmacy, laboratory, and medical care to more than a third of insured individuals in California. KPSF has been chosen as the study site given the disproportionate burden of HIV in this KPNC service area. At KPSF, there are 121 Adult and Family Medicine (AFM) PCPs serving approximately 189,000 patients.
Subjects. The study team will recruit 10-15 PCPs each from the two KPSF clinical sites in San Francisco prior to randomization. Providers will be recruited at routine staff meetings and through email invitations for a one-time, 60- minute, audio-recorded focus group. The study team will assess what information PCPs would like to have included in the clinical decision support tool. Recognizing that time constraints are a barrier to all healthcare interventions, we will seek feedback from PCPs regarding their preferences for intervention delivery and timing, as well as their perceptions of facilitators and barriers to acting on the intervention. Open-ended questions will minimize bias and allow for unanticipated themes to emerge.
Randomization. PCPs who meet study criteria and do not opt-out will be randomized to one of the two study arms in a 1:1 ratio. There are 12 providers who care for both HIV-infected and uninfected patients, and allocation of this subset of providers will be balanced between the trial arms. To ensure this, the study team will use simple randomization to assign the 13 PCPs who care for both HIV-infected and uninfected patients to intervention or usual care and then use simple randomization again to assign the remaining 109 PCPs.
Specificity of the prediction model. The prediction model acts as a screening test to be followed by a provider's clinical evaluation. The study team expects that some patients with scores indicating an elevated risk for HIV acquisition will not have clinical indications for PrEP. The relationship between PCPs and patients is critical given the sensitive nature of sexual health discussions. In addition, prior to initiation of treatment with PrEP, patients will attend visits where a member of the dedicated KPSF PrEP team (NP or MD) will assess HIV risk and discuss PrEP indications, follow-up, side effects, and contraindications.
Scalability of the intervention outside KPNC. Even if the intervention is successful within KPNC, other health settings outside KPNC will need to adopt technology solutions to update risk scores, automate lists of patients with elevated risk scores, identify eligible appointments, and successfully deliver interventions to providers. While the study team's robust model that included 44 EHR variables provided the greatest predictive value for incident HIV, simpler models that included only a handful of key variables also improved identification of patients who may benefit from PrEP. The study results will provide a roadmap for successful implementation at other institutions, even if technology and EHR resources are more limited.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention | Experimental | Behavioral: Point-of-care decision support intervention |
| Usual Care | No intervention | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Primary care provider at Kaiser Permanente San Francisco Medical Center
- Provide primary care to adult patients
- more than 150 people without HIV on their primary care physician panel.
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Point-of-care decision support interventionPCPs notified by EHR messages if they had an upcoming in-person or video visit with an eligible patient who had a predicted risk of incident HIV diagnosis of 0.2% or higher. Study team members manually sent messages marked as "high priority" one business day prior to scheduled visits, alerting PCPs that a patient may be at increased risk for acquiring HIV and may benefit from a conversation about PrEP. Additional information was provided about the study, the prediction model, clinical indications for PrEP, strategies for initiating discussions about HIV prevention and PrEP, and how to refer patients to KPSF's PrEP program. Messages did not include the numeric predicted HIV risk from the model. PCPs received a maximum of two messages per day; with the two patients with the highest predicted risk were selected. Patient with multiple visits were flagged no more than once monthly. | Behavioural | Intervention |
Primary outcome
Cumulative risk (%) of linkage to PrEP
Time frame: Within 90 days after PrEP referral.
linkage to PrEP care within 90 days of the first encounter, defined as first of following: PrEP discussion (ICD-10 Z29.8), referral (measured by PrEP referrals and appointments booked through e-consult, a provider-to-provider community platform embedded in the EHR ), or prescription fill for emtricitabine coformulated with tenofovir disoproxil fumarate or with tenofovir alafenamide
3 secondary outcomes
Cumulative risk (%) of PrEP Prescription fill only
Time frame: Within 90 days after first encounter
Cumulative risk (%) of HIV Testing
Time frame: within 90 days of first encounter
Cumulative risk (%) of STI Testing
Time frame: within 90 days of first encounter
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Aug 2023.
- Derived from this study: PubMed 38412047Volk JE, Leyden WA, Lea AN, Lee C, Donnelly MC, Krakower DS, Lee K, Liu VX, Marcus JL, Silverberg MJ. Using Electronic Health Records to Improve HIV Preexposure Prophylaxis Care: A Randomized Trial. J Acquir Immune Defic Syndr. 2024 Apr 1;95(4):362-369. doi: 10.1097/QAI.0000000000003376.
- Individual participant dataSharing planned: No. There is no plan to make individual participant data available to other researchers.
Related trials for Pre-Exposure Prophylaxis
Active, not recruiting
Evaluating the Effectiveness of a Mobile HIV Prevention App to Increase HIV and Sexually Transmitted Infections (STI) Testing and PrEP Initiation Among Rural Men Who Have Sex With Men
HIV Infections, STI
Not yet recruitingPhase 4
Starting HIV Prevention Medicine (PrEP) During an Emergency Department Visit With a Peer Navigator
HIV Prevention, Pre-Exposure Prophylaxis (PrEP)
Not yet recruiting
Evaluating the Healthy Families PrEP Program for Women at Risk for HIV
HIV, Pregnancy
RecruitingObservational study
Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
HIV Infections
Active, not recruiting
CAMELLIA Cohort: A Longitudinal Study to Understand Sexual Health and Prevention Among Women in Alabama
Hiv, Sexually Transmitted Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Point-of-care decision support intervention in people with Pre-Exposure Prophylaxis, run by Kaiser Permanente at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cumulative risk (%) of linkage to PrEP (time frame: Within 90 days after PrEP referral.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05991869, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Aug 2023.